Clostridium difficile infection and concurrent vancomycin-resistant Enterococcus stool colonization in a health care worker: Case report and review of the literature

2003 ◽  
Vol 31 (1) ◽  
pp. 54-56 ◽  
Author(s):  
Amy J. Ray ◽  
Curtis J. Donskey
2019 ◽  
Vol 6 (4) ◽  
pp. 163-169
Author(s):  
Leonardo F. Jurado ◽  
Bibiana Pinzón ◽  
Zandra R. De La Rosa-Noriega ◽  
Eugenio Matijasevic ◽  
Rocío del Pilar López-Panqueva

2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Erik R. Dubberke ◽  
Kathleen M. Mullane ◽  
Dale N. Gerding ◽  
Christine H. Lee ◽  
Thomas J. Louie ◽  
...  

Abstract Background.  Vancomycin-resistant Enterococcus (VRE) is a major healthcare-associated pathogen and a well known complication among transplant and immunocompromised patients. We report on stool VRE clearance in a post hoc analysis of the Phase 2 PUNCH CD study assessing a microbiota-based drug for recurrent Clostridium difficile infection (CDI). Methods.  A total of 34 patients enrolled in the PUNCH CD study received 1 or 2 doses of RBX2660 (microbiota suspension). Patients were requested to voluntarily submit stool samples at baseline and at 7, 30, and 60 days and 6 months after the last administration of RBX2660. Stool samples were tested for VRE using bile esculin azide agar with 6 µg/mL vancomycin and Gram staining. Vancomycin resistance was confirmed by Etest. Results.  VRE status (at least 1 test result) was available for 30 patients. All stool samples for 19 patients (63.3%, mean age 61.7 years, 68% female) tested VRE negative. Eleven patients (36.7%, mean age 75.5 years, 64% female) were VRE positive at the first test (baseline or 7-day follow-up). Of these patients, 72.7%, n = 8 converted to negative as of the last available follow-up (30 or 60 days or 6 months). Of the other 3: 1 died (follow-up data not available); 1 patient remained positive at all follow-ups; 1 patient retested positive at 6 months with negative tests during the interim. Conclusions.  Although based on a small sample size, this secondary analysis demonstrated the possibility of successfully converting a high percentage of VRE-positive patients to negative in a recurrent CDI population with RBX2660.


Author(s):  
Steffen Höring ◽  
◽  
Doris Keller ◽  
Michael Kleines ◽  
◽  
...  

Coronavirus-specific antibodies decline fast and allow reinfection starting 6 months post infection. Knowledge on reinfection is very important for SARS-CoV-2. Here we report a reinfection with SARS-CoV-2 of a 23 years old female health care worker 177 days after the onset of the first episode. The second episode was clinically more severe as the first episode. Our data show that reinfection with SARS-CoV-2 can occur with increased clinical impact in immunocompetent, young individuals after less than half a year.


2017 ◽  
Vol 76 (5) ◽  
pp. 225-227
Author(s):  
Atsunori Sugita ◽  
Kosaku Kinoshita ◽  
Tomohide Komatsu ◽  
Rumi Tagami ◽  
Shingo Ihara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document